NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $2.12 +0.02 (+0.95%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.00 (+0.24%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compass Therapeutics Stock (NASDAQ:CMPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compass Therapeutics alerts:Sign Up Key Stats Today's Range$2.09▼$2.1750-Day Range$1.46▼$2.2452-Week Range$0.77▼$4.08Volume464,494 shsAverage Volume925,257 shsMarket Capitalization$293.16 millionP/E RatioN/ADividend YieldN/APrice Target$13.13Consensus RatingBuy Company OverviewCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More… Compass Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreCMPX MarketRank™: Compass Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 194th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompass Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.86% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Compass Therapeutics has recently decreased by 9.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.86% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Compass Therapeutics has recently decreased by 9.44%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.14 News SentimentCompass Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Compass Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have sold 10,841.37% more of their company's stock than they have bought. Specifically, they have bought $51,900.00 in company stock and sold $5,678,571.00 in company stock.Percentage Held by Insiders29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Stock News HeadlinesCompass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J. Schuetz Purchases 10,000 SharesMay 28 at 5:46 AM | insidertrades.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28 at 8:00 AM | globenewswire.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 29, 2025 | Brownstone Research (Ad)Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $13.13May 25, 2025 | americanbankingnews.comStifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)May 11, 2025 | theglobeandmail.comCompass Therapeutics price target lowered to $10 from $12 at GuggenheimMay 9, 2025 | msn.comCompass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.comCompass Therapeutics to Participate in Upcoming May Investor EventsMay 6, 2025 | globenewswire.comSee More Headlines CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $1.45 at the beginning of the year. Since then, CMPX stock has increased by 46.2% and is now trading at $2.12. View the best growth stocks for 2025 here. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Compass Therapeutics' top institutional shareholders include MPM Bioimpact LLC (6.11%), Adage Capital Partners GP L.L.C. (2.87%), Affinity Asset Advisors LLC and SG Americas Securities LLC (0.68%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz, Vered Bisker-Leib and Jonathan Anderman. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today5/29/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPX CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$13.13 High Stock Price Target$32.00 Low Stock Price Target$5.00 Potential Upside/Downside+519.1%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.49 million Net MarginsN/A Pretax Margin-5,618.71% Return on Equity-32.37% Return on Assets-30.67% Debt Debt-to-Equity RatioN/A Current Ratio31.84 Quick Ratio31.84 Sales & Book Value Annual Sales$850,000.00 Price / Sales344.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.81Miscellaneous Outstanding Shares138,283,000Free Float98,376,000Market Cap$293.16 million OptionableNot Optionable Beta1.40 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CMPX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.